Discharge Recommendations for Gout
For patients discharged after an acute gout flare, initiate urate-lowering therapy (ULT) with low-dose allopurinol (≤100 mg/day, lower if CKD stage ≥3) along with mandatory anti-inflammatory prophylaxis (colchicine, NSAIDs, or prednisone) for 3-6 months to prevent recurrent flares. 1
Acute Flare Management at Discharge
Anti-inflammatory Treatment
Ensure the patient is discharged with one of the following for ongoing acute flare management 1, 2:
Corticosteroids (preferred first-line): Prednisone 35 mg daily for 5 days
- Safest option with fewer adverse effects than NSAIDs
- Contraindicated only in systemic fungal infections
NSAIDs: Any NSAID is equally effective (no evidence indomethacin is superior)
- Avoid in renal disease, heart failure, or cirrhosis
Colchicine: 1.2 mg followed by 0.6 mg one hour later, then 0.5 mg 2-3 times daily 2, 3
- Reduce dose in CKD or with CYP3A4/P-glycoprotein inhibitors
- Stop or reduce if diarrhea develops (first sign of toxicity)
Critical pitfall: Avoid opioids—they are prescribed in 28-30% of ED discharges despite availability of effective anti-inflammatory treatments 4, 5. This represents inappropriate management and contributes to the opioid epidemic.
Urate-Lowering Therapy (ULT) Initiation
When to Start ULT at Discharge
Start ULT even during an active flare if the patient meets criteria 1:
- ≥2 gout attacks per year
- Presence of tophi
- Chronic kidney disease
- Urolithiasis
- Radiographic evidence of gouty arthropathy
Do NOT start ULT after a first attack or with infrequent attacks (<2/year) 2
ULT Regimen
Allopurinol is the preferred first-line agent for all patients, including those with CKD stage ≥3 1:
- Starting dose: ≤100 mg/day (≤50 mg/day in CKD stage ≥3)
- Titration: Gradually increase every 2-4 weeks to achieve target serum urate <6 mg/dL (or <5 mg/dL if tophi present)
- May require doses >300 mg/day even in CKD to reach target
- Monitor for allopurinol hypersensitivity syndrome (AHS), especially in CKD patients
Alternative agents:
- Febuxostat: Start ≤40 mg/day if allopurinol contraindicated
- Probenecid: Start 500 mg once or twice daily (avoid in CKD stage ≥3)
Mandatory Flare Prophylaxis with ULT
This is non-negotiable: When starting ULT, you MUST prescribe concomitant anti-inflammatory prophylaxis 1:
- Duration: 3-6 months minimum (NOT <3 months)
- Options: Low-dose colchicine (0.6 mg daily or twice daily), low-dose NSAIDs, or prednisone 5-10 mg daily
- Rationale: ULT initiation triggers flares in the first 6 months; prophylaxis reduces this risk significantly
- Continue beyond 6 months if patient continues experiencing flares
Common pitfall: Studies show only 5-18% of hospitalized gout patients have ULT initiated or recommended at discharge 6. This represents a massive lost opportunity for long-term disease control.
Patient Education at Discharge
Provide explicit instructions on:
- Self-medication for future flares: Prescribe a pre-defined treatment plan to start within 12 hours of flare onset 3
- Gout is chronic: Requires long-term ULT, not just acute treatment
- Do not stop ULT during a flare: This is a common misconception
- Lifestyle modifications: Weight loss, limit alcohol (especially beer), reduce purine-rich foods (organ meats, shellfish), avoid diuretics when possible 7
Monitoring Plan
Serum urate: Check 2-4 weeks after ULT initiation, then periodically during dose titration
- Target: <6 mg/dL (360 μmol/L) for most patients
- Target: <5 mg/dL (300 μmol/L) if tophi present 7
Renal function: Monitor when titrating allopurinol, especially in CKD
Flare frequency: Assess at follow-up to determine if prophylaxis duration needs extension
Follow-up Timing
Schedule outpatient rheumatology or primary care follow-up within 2-4 weeks to:
- Assess response to ULT
- Titrate ULT dose based on serum urate
- Evaluate for adverse effects
- Screen for cardiovascular comorbidities (hypertension, diabetes, hyperlipidemia) 8
Key takeaway: The discharge period is a critical opportunity to initiate definitive long-term management. Failure to start ULT with prophylaxis in appropriate patients perpetuates the cycle of recurrent flares and progressive joint damage.